Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Biotechnology

Healthcare
$10.19 -1.58%

-$0.19 today

Market cap
$859.56M
Beta
0.84
P/E (TTM)
-24.1
EPS (TTM)
-$0.49
52W Low $3.55High $26.95

Volume 0.99M

Average 1.49M

CRVS Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Corvus Pharmaceuticals, Inc.NASDAQ: CRVS

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 387.9% from a year ago

Total equity stood at $240.68M at the end of Q1 FY2026, up 387.9% from a year earlier and up 293.2% from the prior quarter. Over 3 fiscal years it compounded at +2.9% a year.

Context

  • Total equity amounted to 95.1% of total assets at the end of Q1 FY2026, up 12.1 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +387.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$240.68M+293.2% QoQ
Last fiscal yearDec 2025
$61.21M+87.9% YoY
Year agoMar 2025
$49.33M+387.9% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+387.9%——
1 year+87.9%——
3-year CAGR+2.9%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
61.21M USD
Year-over-year change
+87.9%
4-year CAGR
-10.9%

Total Equity vs competitors

How CRVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +387.9% is the 3rd highest of 10, against a peer median of +67.0%.
  • Total equity amounts to 95.1% of total assets for CRVS, versus a peer median of 50.2%.
CRVS Competitors
Total Equity for CRVS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NKTRNektar TherapeuticsJun 2026$903.12M USD+3830.2%-37.4%82.5%
RCUSArcus Biosciences, Inc.Jun 2026$464M USD-15.5%-1.3%50.2%
CTMXCytomX Therapeutics, Inc.Mar 2026$319.94M USD+1177.3%—89.0%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$240.68M USD+387.9%+2.9%95.1%
CMPXCompass Therapeutics, Inc.Mar 2026$186.47M USD+69.1%+2.7%90.9%
CGENCompugen Ltd.Mar 2026$95.35M USD+67.0%+9.8%65.4%
CHRSCoherus Oncology, Inc.Mar 2026$78.62M USD+142.9%—29.6%
ADAGAdagene Inc.Dec 2025$35.35M USD-30.0%-24.8%45.2%
MGNXMacroGenics, Inc.Mar 2026$21.2M USD-73.2%-26.8%9.7%
IPHAInnate Pharma S.A.Dec 2025-€21.69M EUR-345.6%—34.6%
Peer median (excluding CRVS) —+67.0%-13.1%50.2%

Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents63.46M13.16M12.62M8.74M4.58M
Short-term Investments5.99M29.14M14.53M43.22M52.17M
Net Receivables539K633K63K216K374K
Inventory00000
Other Current Assets128K102K220K548K318K
Total Current Assets71.31M43.66M27.96M54.41M58.21M
Property, Plant & Equipment (Net)3.64M2.57M1.39M1.33M1.06M
Goodwill00000
Intangible Assets00000
Long-term Investments34.27M21.88M16.12M12.54M10.99M
Tax Assets00000
Other Non-current Assets236K129K89K632K855K
Total Non-current Assets38.14M24.58M17.6M14.5M12.91M
Total Assets109.46M68.24M45.55M68.91M71.12M
Account Payables1.57M1.98M1.53M2.58M2.49M
Short-term Debt0000403K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.97M1.27M929K30.02M5.85M
Total Current Liabilities9.69M10.75M6.87M35.4M9.38M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities2.6M1.37M0937K534K
Total Liabilities12.29M12.13M6.87M36.34M9.91M
Common Stock5K5K5K7K7K
Retained Earnings(266.38M)(307.69M)(334.72M)(397.01M)(412.29M)
Accumulated OCI1.87M(563K)(967K)(1.29M)(896K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity97.16M56.12M38.68M32.57M61.21M
Total Debt3.65M2.6M1.37M1.12M937K
Net Debt(59.81M)(10.56M)(11.25M)(7.62M)(3.64M)

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Intrinsic Alpha fair value

Locked

Current Price

$10.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.